Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agenus Inc (NQ: AGEN )

1.460 +0.010 (+0.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,381,905
Open 1.450
Bid (Size) 1.450 (74)
Ask (Size) 1.470 (48)
Prev. Close 1.450
Today's Range 1.420 - 1.500
52wk Range 1.250 - 3.370
Shares Outstanding 348,875,959
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Agenus to Participate in Jefferies Healthcare Conference
From Agenus
Via Business Wire
Agenus (AGEN) Q1 2023 Earnings Call Transcript
AGEN earnings call for the period ending March 31, 2023. 
Via The Motley Fool

Performance

YTD
-39.17%
-39.17%
1 Month
-3.31%
-3.31%
3 Month
-29.13%
-29.13%
6 Month
-44.49%
-44.49%
1 Year
-12.57%
-12.57%

More News

Read More
Agenus Provides Corporate Update and First Quarter 2023 Financial Results
From Agenus Inc.
Via Business Wire
Agenus Selected for Late-Breaking Oral Presentation at ESMO-GI
From Agenus
Via Business Wire
Agenus' Investigational Cancer Combo Therapy Shows 33% Durable Responses In Ovarian Cancer
Via Benzinga
Why Agenus Stock Is Slumping This Week
Via The Motley Fool
Agenus (AGEN) Q4 2022 Earnings Call Transcript
Via The Motley Fool
Agenus (NASDAQ: AGEN) Featured in Coverage of the Inaugural EF Hutton Global Conference
Via Investor Brand Network
Agenus to Present at the American Society of Clinical Oncology 2023 Annual Meeting
From Agenus
Via Business Wire
Agenus to Provide Corporate Update and First Quarter 2023 Financial Report
From Agenus
Via Business Wire
Agenus to Participate in May Investor Conferences
From Agenus
Via Business Wire
Earnings Preview For Agenus
Via Benzinga
Why Travelers Companies Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
These 3 Nasdaq Stocks Are on Fire Today: Here's Why
Via The Motley Fool
Agenus Receives Fast Track Designation for Botensilimab and Balstilimab in Colorectal Cancer
From Agenus Inc.
Via Business Wire
Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer
From Gain Therapeutics, Inc.
Via GlobeNewswire
Why Agenus, Amarin, and Axsome Therapeutics Shares Slumped Today
Via The Motley Fool
Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics
From Agenus Inc.
Via Business Wire
Agenus’ Botensilimab in Combination with Balstilimab Shows 33% Durable Responses in Ovarian Cancer
From Agenus Inc.
Via Business Wire
Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives
From Agenus Inc.
Via GlobeNewswire
Illumina, Seagen And Other Big Stocks Moving Higher On Monday
Via Benzinga
Agenus Cancels Conference Call to Discuss the Company’s Minority Cash Holdings at SVB in Light of Government’s SVB Deposit Access Announcement
From Agenus Inc.
Via GlobeNewswire
Agenus Schedules Conference Call to Discuss the Company’s Minority Cash Holdings at SVB
From Agenus Inc.
Via GlobeNewswire
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2022 Financial Report
From Agenus Inc.
Via GlobeNewswire
Agenus to Present Botensilimab Data in Oral Plenary Session at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer
From Agenus Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.